# US 2013/0253449 A1 · Noradrenergic and specific serotonergic antidepressant-containing transdermal patch

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253449 A1
- Document ID: US20130253449A1
- Status: Published application
- Kind: A1
- Application number: 13/992,375
- Filed: 2011-12-06
- Published: 2013-09-26
- Earliest claimed: 2010-12-07
- Assignees: Yutoku Pharmaceutical Industries Co., Ltd.
- Inventors: Makoto Yoshitake; Takayuki Ogawa; Takashi Yoshitake
- Web page: https://patentgrep.com/patent/US20130253449A1

## CPC

- A61K 9/7084: {Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches}
- A61K 9/7053: {obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene}
- A61K 9/7061: {Polyacrylates}
- A61K 9/7076: {the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins}
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/24: Antidepressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention is a transdermal patch containing a noradrenergic and specific serotonergic antidepressant (NaSSA) such as mirtazapine or the like as the active ingredient therein, and capable of transdermally and quantitatively administering the active ingredient. Further, the transdermal patch of the invention exhibits a sufficient therapeutical effect, can suppress side effects that are problematic in oral administration, improves patient compliance and quality of life (QOL), and can solve various problems. Preferably, the patch provided by the invention contains the active ingredient in an amount of from 2 to 30% by mass relative to the drug-containing layer.

## Claims

### Claim 1

A transdermal patch, comprising:
a support,
a drug-comprising layer, and
a release liner,
wherein the drug-comprising layer comprises a noradrenergic and specific serotonergic antidepressant as an active ingredient therein.

### Claim 2 (depends on 1)

The transdermal patch of claim 1, wherein a content of the noradrenergic and specific serotonergic antidepressant is of from 2 to 30% by mass relative to the drug-comprising layer.

### Claim 3 (depends on 1)

The transdermal patch of claim 1, wherein a content of the noradrenergic and specific serotonergic antidepressant is of from 3 to 25% by mass relative to the drug-comprising layer.

### Claim 4 (depends on 1)

The transdermal patch of claim 1, further comprising an adhesive base material as a base ingredient in the drug-comprising layer,
wherein the adhesive base material is at least one selected from the group consisting of a rubber adhesive base material, an acrylic polymer, and a silicone polymer.

### Claim 5 (depends on 1)

The transdermal patch of claim 1, wherein the drug-comprising layer further comprises a transdermal absorption promoter.

### Claim 6 (depends on 5)

The transdermal patch of claim 5, wherein a content of the transdermal absorption promoter is of from 1 to 10% by mass relative to the drug-comprising layer.

### Claim 7 (depends on 5)

The transdermal patch of claim 5, wherein the transdermal absorption promoter is at least one selected from the group consisting of a myristate, a sebacate, menthol, polyoxyethylene oleyl ether, and Polysorbate 80™.

### Claim 8 (depends on 1)

The transdermal patch of claim 1, wherein the drug-comprising layer further comprises an antioxidant.

### Claim 9 (depends on 8)

The transdermal patch of claim 8, further comprising at least one antioxidant selected from the group consisting of ascorbic acid, an ester of ascorbic acid, a phenolic antioxidant, and 2-mercaptobenzimidazole.

### Claim 10 (depends on 9)

The transdermal patch of claim 9, wherein the at least one antioxidant is a phenolic antioxidant, which is dibutylhydroxytoluene.

### Claim 11 (depends on 9)

The transdermal patch of claim 9, wherein the at least one antioxidant is
ascorbic acid, which is isoascorbic acid;
an ester of ascorbic acid, which is L-ascorbyl palmitate; or
both.

### Claim 12 (depends on 9)

The transdermal patch of claim 9, wherein the at least one antioxidant is
L-ascorbyl palmitate in an amount of from 0.02 to 0.2% by mass relative to the drug-comprising layer, and
dibutylhydroxytoluene in an amount of from 0.1 to 1% by mass relative to the drug-comprising layer.

### Claim 13 (depends on 8)

The transdermal patch of claim 8, wherein
the drug-comprising layer is a matrix adhesive layer that further comprises: a base ingredient,
and
the antioxidant is in a dissolved state.

### Claim 14 (depends on 13)

The transdermal patch of claim 13, wherein the base ingredient comprises at least one adhesive base material selected from the group consisting of a rubber adhesive base material, an acrylic polymer, and a silicone polymer.

### Claim 15 (depends on 14)

The transdermal patch of claim 14, wherein the at least one adhesive base material is a rubber adhesive base material.

### Claim 16 (depends on 1)

The transdermal patch of claim 1, wherein the noradrenergic and specific serotonergic antidepressant is mirtazapine.
